Full Breakdown
Merck Restructures to Address Keytruda Patent Cliff
2/23/2026, 8:06:04 PM
Merck's Strategic Business Split
On February 23, 2026, Merck & Co. announced a significant restructuring of its Human Health division, creating two distinct units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases unit. This move is primarily aimed at addressing the impending patent expiration of its leading cancer drug, Keytruda, which has been a major revenue driver for the company. Keytruda generated approximately $31.7 billion in 2025, accounting for nearly 46% of Merck's total revenue, and is projected to face loss of exclusivity in the U.S. by 2028.
Background and Context
Merck's decision to split its business comes as the company seeks to diversify its portfolio beyond Keytruda and other legacy medications. The restructuring follows a trend in the pharmaceutical industry where companies like Novartis and Pfizer have similarly reorganized their operations to enhance focus on oncology. Merck has significantly expanded its pipeline since 2021, acquiring companies such as Cidara Therapeutics and Verona Pharma for approximately $10 billion to bolster its offerings.
Leadership Changes
To lead the new Oncology Business Unit, Merck appointed Jannie Oosthuizen as Executive Vice President and President. Oosthuizen has a long history with Merck, having previously overseen the U.S. Human Health business. Additionally, Brian Foard, formerly of Sanofi, has been brought in as Executive Vice President and President of the Specialty, Pharma & Infectious Diseases unit, effective March 2, 2026. This leadership restructuring is intended to enhance the execution of Merck's commercial strategy as it navigates the challenges posed by the patent cliff.
Official Statements & Responses
Merck's CEO, Robert Davis, expressed confidence in the company's future, stating, “Our belief in our ability to have substantial growth once we get closer to the [loss of exclusivity] is as high as it’s ever been.” He emphasized that the company has the "broadest and widest pipeline" it has seen in years, projecting potential annual revenues exceeding $70 billion by the middle of the next decade.
Criticism & Opposition
Despite the optimistic outlook, analysts have cautioned that Merck must improve its commercial execution and pipeline delivery to mitigate the financial impact of Keytruda's patent expiration. Citi analysts noted that while the split helps clarify Merck's oncology portfolio, further work is needed to offset the pressures from upcoming loss-of-exclusivity scenarios.
What's Next
Moving forward, Merck aims to sustain its leadership in oncology while expanding its presence in other therapeutic areas, including cardiometabolic medicine and infectious diseases. The company is preparing for over 80 ongoing Phase 3 studies and anticipates launching more than 20 new growth drivers in the coming years.
Verbatim Quotes
- “Our belief in our ability to have substantial growth once we get closer to the [loss of exclusivity] is as high as it’s ever been,” — Robert Davis, CEO of Merck
- “The company now has more optionality to separate or spin off one of these businesses in the future,” — James Harlow, Senior Vice President at Novare Capital Management
